Compare Mattel Inc (MAT) vs Pfizer Inc (PFE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Mattel Inc vs Pfizer Inc — how do they compare? Mattel Inc trades at $16.7 (market cap $4.68B), while Pfizer Inc trades at $27.78 (market cap $159.59B). The key difference: Pfizer Inc is far larger — about 34.1× Mattel Inc's market cap, and Pfizer Inc pays a 6.14% dividend while Mattel Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Mattel Inc for 97 Days and Pfizer Inc for 158 Days on average.
| MAT | PFE | |
|---|---|---|
Market Cap | $4.68B | $159.59B |
Volume | 11,617,958 | 30,937,010 |
Sector | Consumer Cyclical | Health |
52-Week High | $22.16 | $29.02 |
52-Week Low | $12.66 | $23.67 |
Typical Hold Time | 97 Days | 158 Days |
Enterprise Value | $6.90B | $211.09B |
Dividend Yield | — | 6.14% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Mattel (MAT) trades at $16.58, up 4.08% on takeover speculation from Authentic Brands Group, with technical indicators showing bullish momentum despite overbought RSI levels. The company maintains solid fundamentals with $5.35B revenue, 7.78% net margin, and attractive valuation at 12.22 P/E ratio. Recent CEO transition to Roger Lynch and potential acquisition interest create significant near-term catalysts.
The stock presents upside potential given the $18 high price target and bullish analyst consensus (53% buy ratings), though execution risks under new leadership and mixed earnings history warrant caution. The takeover premium provides support, but investors should monitor Q3 earnings delivery against the 0.974 EPS expectation for sustained momentum.
Pfizer (PFE) trades at $27.82, up 1.22% with a bullish technical signal from moving averages. The company shows stable revenue around $62-63B with consistent earnings beats in recent quarters. Analysts maintain a $29.40 consensus target with 40% buy ratings. Recent news highlights Pfizer's focus on obesity and oncology pipelines as key growth drivers.
Pfizer offers value with defensive cash flows and dividend stability, though patent cliffs and margin compression present challenges. The stock's current valuation appears reasonable relative to sector peers, with upside potential if pipeline developments succeed. Key risks include competitive pressures and regulatory hurdles for new drug approvals.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Mattel Inc
Mattel markets toy products that are sold to its wholesale customers and direct to retail consumers. The company offers products for children and families, including toys for infants and preschoolers, girls and boys, youth electronics, handheld and other games, puzzles, educational toys, media-driven products, and plush and fashion-related toys. Mattel's owned portfolio includes Barbie, Hot Wheels, Fisher-Price, Thomas & Friends, and American Girl. In addition, it currently manufactures toy products for its segments both internally and externally (through manufacturing partners). Just over half of its net sales are in North America, while the remainder stem from international markets.
Read more on MAT →About Pfizer Inc
Pfizer Inc. operates as a pharmaceutical company. The Company offers medicines, vaccines, medical devices, and consumer healthcare products for oncology, inflammation, cardiovascular, and other therapeutic areas. Pfizer serves customers worldwide.
Read more on PFE →
